Blood-Based Biomarkers in Patients with Non-small Cell Lung Cancer Treated with Immune Checkpoint Blockade

The authors review studies in which multiple blood-based biomarkers encompassing circulating soluble analytes, immune cell subsets, circulating tumor DNA, blood-based tumor mutational burden, and circulating tumor cells have shown promising associations with the clinical response of non-small cell lung cancer patients to immune checkpoint inhibitors therapy.